The UK and US have announced a key bilateral deal that will ensure no tariffs on British drug shipments being sold in the American market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to boost spending on medicines through the National Health Service (NHS). This pledge guarantees that duties on these key goods will stay at nothing for a duration of 36 months.
This development is in response to previous warnings to significantly raise import taxes on patented drug imports, with potential rates mentioned as high as one hundred percent.
"This deal between the Britain strengthens the global environment for new treatments and brings much-needed equity to transatlantic pharmaceutical trade," an announcement said.
Commercial Importance
Medicines represent one of the the United Kingdom's largest goods shipped to the United States, which is by far the largest buyer for large UK drugmakers.
Trade data show that in the year leading up to September, the UK exported drugs worth billions to the US. This figure accounted for 17.4% of all goods exports in that span.
"This guarantee secures jobs, stimulates capital expenditure and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official remarked.
Specific UK Commitments
The deal involves several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to double total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. Previously, rebates exceeded twenty percent.
Industry Background
This agreement takes place against a long-running dispute between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
These tensions were intensified by claims that US customers were paying a premium for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been delayed or scrapped, while major funding commitments have been announced toward US facilities.
A senior figure publicly accepted that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a share of its resources over the last ten years.
